|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Proportion of patients with non-squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed a moderate or strong correlation with median PFS.
|
28959160 |
2017 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Consistent with these findings, recent clinical studies have shown that epidermal growth factor receptor-mutant lung ADC can transdifferentiate to SCC in relapsed cancer patients.
|
28284717 |
2017 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR TKIs could be an option for the treatment of SCC, and EGFR mutation detection can help to select a subgroup of patients who would have the best response to TKIs.
|
26725853 |
2016 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Paired genomic analysis from our sample provides early clinical evidence of the ADC to SCC lineage transition that might be provoked by an alteration in the PI3K/AKT/mTOR pathway during EGFR TKI treatment.
|
31319998 |
2019 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) gene mutations are associated with the sensitivity of non-small cell lung carcinomas (NSCLCs) to gefitinib, but such findings have not been reported in squamous cell carcinomas of the head and heck (SCCHNs).
|
18097577 |
2008 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present review presents a critical discussion about the following issues based on the results of clinical studies: (1) whether or not the assessment of the EGFR mutation status in NSCLC patients is indispensable; (2) whether gefitinib and erlotinib have different effects; (3) the need to sub-classify NSCLC by histologic type; (4) significance of maintenance therapy for NSCLC; and (5) whether platinum-doublet chemotherapy plus bevacizumab is a standard treatment for non-squamous cell carcinoma.
|
21775064 |
2012 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Detailed morphologic and immunohistochemical reevaluation of EGFR/KRAS-mutant "SQCC" identified during clinical genotyping (n = 16) resulted in reclassification of 10 (63%) cases as AD-SQC and five (31%) cases as poorly differentiated adenocarcinoma morphologically mimicking SQCC (i.e., adenocarcinoma with "squamoid" morphology).One (6%) case had no follow-up.
|
22228640 |
2012 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3].
|
27987587 |
2016 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The mutation rate of the EGFR of squamous cell carcinoma patients was significantly higher than that of adenocarcinoma patients (P < 0.05).
|
29516969 |
2018 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The current guidelines do not advise to perform EGFR-mutation analysis in unequivocal squamous cell carcinoma (SqCC).
|
25982011 |
2015 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to clarify the incidence and prognosis related to MCPyV infections in NSCLC.Tissue samples from 167 NSCLC patients (92 with squamous cell carcinomas [SCCs] and 75 with adenocarcinomas) were analyzed for the presence of MCPyV and EGFR mutations.
|
28099328 |
2017 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large cell carcinomas (LC), and three adenosquamous carcinomas] that had not been exposed to the TKI therapies, and found 12 (8.2%; 12/147) EGFR T790M mutation in eight AD (11.4%), three SQ (4.8%), and one LC (8.3%) by the PNA-clamping PCR.
|
21635547 |
2011 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations were not associated with TAA expression for either histology and were three times more frequent in adenocarcinomas than in squamous cell carcinomas tumors.
|
27519286 |
2017 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We examined EGFR mutations in 288 head and neck squamous cell carcinomas and 58 head and neck papillomas or polyps.
|
30117182 |
2018 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We only found EGFR (8.0%), c-Met (2.8%), and PIK3CA (2.6%) alterations in the non-smoker with squamous cell carcinoma (SCC) subgroup.
|
22768234 |
2012 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gene copy number and protein status of EGFR were investigated in microarrayed tumors from 183 NSCLC patients, including squamous cell carcinoma (SCC; 89 patients) and non-SCC (94 patients) histologies.
|
12953099 |
2003 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant.
|
30268457 |
2018 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The lack of identification of mutation in the tyrosine 1045 codon of EGFR suggests that mutations in this region may be relatively rare in oral squamous cell carcinomas.
|
23991943 |
2013 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that EGFR mutations were more prevalent in never-smokers (83.3% versus 16.7%, p = 0.006) and patients diagnosed as NSCC favor SqCC (46.2% versus 5.2%, p = 0.001).
|
31221183 |
2019 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Along the LTRs, all but the SCC had EGFR mutations, whereas the RPs had no EGFR, but k-ras mutations in 5/11 cases.
|
22483783 |
2012 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to examine the diagnostic accuracy on lung cancer small biopsies for the distinction between adenocarcinoma and squamous cell carcinoma and relate these to immunohistochemical and KRAS and EGFR mutation analysis.
|
23064619 |
2012 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Such putative EGFR autocrine loop activation was found in 73% of squamous cell carcinomas that rarely develop ras mutations.
|
10963846 |
2000 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The final frequency of the EGFR mutations in true SCC was 3.4% (3/87).
|
21318227 |
2011 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Despite expressing high levels of the epidermal growth factor receptor (EGFR), a majority of oral squamous cell carcinoma (OSCC) patients show limited response to cetuximab and ultimately develop drug resistance.
|
29154973 |
2018 |
|
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations.
|
30401947 |
2019 |